Ciforadenant (** Investigational drug (no approved brand name yet) - developed by Corvus Pharmaceuticals **)

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

Ciforadenant is an investigational drug currently being studied in clinical trials for various advanced cancers, including colorectal cancer. It is an oral medication. In trials for colorectal cancer, it has been studied alone, in combination with another investigational drug called CPI-006, and in combination with both CPI-006 and pembrolizumab (Keytruda). Ciforadenant is being investigated to see if it can help improve the effectiveness of other cancer treatments, like immunotherapy (pembrolizumab) and potentially CPI-006, which targets CD73. It is not yet approved for treating colorectal cancer or any other condition.

Mechanism of Action

Ciforadenant works by blocking a specific receptor in the body called the adenosine 2A receptor. Adenosine is a molecule that can affect the immune system and tumor growth. By blocking this receptor, ciforadenant may help the immune system better recognize and attack cancer cells, potentially enhancing the effects of other cancer therapies like immunotherapy.

Side Effects

As an investigational drug in early-phase trials (Phase 1) The full range of side effects for ciforadenant is still being evaluated. Common side effects observed in trials involving ciforadenant in combination with other drugs have included fatigue Nausea Diarrhea And decreased appetite. Specific side effects related to ciforadenant alone or in combination with CPI-006 and pembrolizumab are still being determined in ongoing studies. Patients participating in clinical trials are closely monitored for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03454451 Phase 1
Archived
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
United States, Australia

Quick Info

Brand Name** Investigational drug (no approved brand name yet) - developed by Corvus Pharmaceuticals **
CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
771 trials
Leucovorin
Other Medications
631 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.